Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
18-Mar-2010
- Canada
Most read news
Topics
Organizations
Viron Therapeutics
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Horizon Discovery Expands Commercial Division with Senior Appointments
Go to page
Prometic Finalizes Major Technology Licencing Agreement in Tunisia
Go to page
pluriSelect GmbH - Leipzig, Germany
Go to page
Faster method to create antibodies for disease research
Go to page
Pharminox signs option to in-license novel telomere signalling targeted agents from Cancer Research Technology
Go to page
To-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases
Go to page
SRI Instruments Europe GmbH - Bad Honnef, Germany
Go to page
Vellore_A._R._Srinivasan
Go to page
Strand Announces Collaboration with Bio-Rad for its Predictive ADME Suite
Go to page
Macfarlane Burnet Institute for Medical Research and Public Health Limited - Melbourne, Australia
Go to page
Cyclacel appoints Nicholas Bacopoulos, Ph.D. to Board of Directors
Go to page
LTKfarma pursues development of proprietary TK therapy
Go to page